Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of “Buy” by Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.36.

Several analysts have recently commented on the company. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird cut their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Vor Biopharma Stock Down 2.2 %

Shares of VOR stock opened at $0.87 on Tuesday. The stock’s 50-day moving average price is $0.83 and its 200 day moving average price is $0.91. The stock has a market capitalization of $59.56 million, a PE ratio of -0.53 and a beta of -0.37. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14.

Vor Biopharma (NYSE:VOR) last released its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). Analysts expect that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC grew its position in shares of Vor Biopharma by 51.4% in the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after purchasing an additional 27,597 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after buying an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma during the second quarter worth $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vor Biopharma in the second quarter valued at $63,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.